ClostraBio says probiotic CLB101 hit safety goal, but posts no numbers
ClostraBio's 48-person placebo-controlled study met its safety endpoint and reported statistically significant secondary gut-symptom results, without disclosing effect sizes or p-values.
Executive Summary
- ClostraBio's first randomized, placebo-controlled human study of its probiotic met its primary safety and tolerability goal and reported statistically significant improvement on secondary gut-symptom measures, based on the company's own topline summary rather than a peer-reviewed or registry-posted dataset.
- The disclosure describes the direction of the secondary results without giving the size of the effect, the statistical values behind it, or the endpoint breakdown, which limits how much confidence the market can place in the claim until fuller data surface.
- The interventional study behind the announcement is small and not built for regulatory purposes, a design that can establish tolerability and a preliminary efficacy signal but not a definitive therapeutic claim.
- CLB101 sits in a probiotic and microbiome field with several similarly early, non-comparator programs targeting gut symptoms, none of which have posted resolved efficacy outcomes that would benchmark this result.
The announcement
ClostraBio said on July 22, 2026, that it completed the first randomized, double-blind, placebo-controlled human study of Anaerostipes caccae CLB101, a butyrate-producing probiotic strain, and that the study met its primary safety and tolerability endpoint. The company also said key secondary efficacy endpoints, including subject-reported outcomes on the validated Gastrointestinal Symptom Rating Scale, showed statistically significant differences versus placebo. ClostraBio's chief executive, Ritu Shah, called the result "the topline results of the first ever gold-standard clinical study conducted with CLB101" and said the company "look forward to sharing complete study results upon publication of the data in a peer-reviewed journal". No effect size, p-value, or confidence interval accompanied the release. ClostraBioClostraBio Announces Positive Results in Landmark Clinical Study with Next-Generation Probiotic CLB101™ and NutraIngredients USA 2026 AwardJul 22, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was done
The trial (NCT07336615) randomized 48 overweight adults with self-reported moderate to severe gastrointestinal symptoms across four arms, using double-blind, placebo-controlled allocation over a four-week treatment period within a study window that ran up to 12 weeks. The registered primary endpoint was adverse events, a safety and tolerability measure, with five secondary endpoints covering blood biomarkers, gastrointestinal symptoms, gut microbiome composition, and intestinal permeability. Eligibility required a Gastrointestinal Symptom Rating Scale score of 4 to 7 and a body mass index between 27 and 35. The trial enrolled by invitation at a single U.S. site rather than open recruitment. NCT07336615A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight IndividualsNCT07336615
What the result establishes
Because the registered primary endpoint was adverse-event incidence rather than an efficacy measure, the trial by design was built to establish tolerability first. The secondary Gastrointestinal Symptom Rating Scale finding the company highlighted was not the primary measure the study was designed and powered around, and no numeric result accompanies the significance claim. A 48-person, single-site study of this kind is suited to generate a preliminary signal, not to establish a definitive efficacy claim, and the sponsor's own framing already anticipates that the fuller dataset will appear later in a peer-reviewed publication. NCT07336615+1A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight IndividualsNCT07336615ClostraBio Announces Positive Results in Landmark Clinical Study with Next-Generation Probiotic CLB101™ and NutraIngredients USA 2026 AwardJul 22, 2026
Operational context
The trial's primary completion date moved once, from February 26, 2026 to April 26, 2026, a single amendment that the registry classifies as a stable change history rather than a pattern of repeated delay. Enrollment held flat at its target of 48 participants with no growth or shortfall against plan, which the underlying operational model flags as a typical, unremarkable enrollment outcome for this design. The study is not registrational, so the result carries no regulatory submission attached to it. NCT07336615A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight IndividualsNCT07336615
Where it sits competitively
CLB101's target and lead mechanism beyond butyrate production are not established in available competitive data, so no first-in-class or isolation claim attaches to this result. The nearest comparable programs are other probiotic and microbiome-modulation studies in gastrointestinal symptoms, including probiotic formulations from AB Biotics and the Center for Applied Health Sciences and a B. lactis strain from Danone Research, none of which the available data ties to a resolved efficacy outcome that would benchmark CLB101's claim. The gut-microbiota field around butyrate production remains mostly early-stage, with programs such as Osel's CBM588 still in Phase 1 testing, meaning the broader mechanism class has not yet produced a validated efficacy readout against which this trial's secondary result can be measured.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.